MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.The Cambridge, MA-based company's
MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.
The Cambridge, MA-based company's main product is MS-325, an MRIcontrast agent designed for the diagnosis of vascular diseases,including coronary artery disease and peripheral vascular disease(SCAN 12/18/96). Epix, formerly known as Metasyn, has formed strategicalliances to develop and commercialize MS-325 with contrast agentproducers Mallinckrodt and Daiichi.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.